Syntello Vaccine Development Kb

Maxim Pharmaceuticals, Inc.

Virovahl, S.a.

Syntello Ab

Syntello Vaccine Development Ab

Virovahl

Anders Vahlne

Lars Rymo

Stig Jeansson

Peter Horal

Bo Svennerholm

Jan Holmgren

Cecil Czerkinsky

Bo Syennerholm

Novel peptides are disclosed which correspond to epitopes of the HIV-1 gp120 protein. These antigenic peptides induce antibody-dependent cellular cytotoxicity against HIV, and thus are useful in immunization against HIV infection and induction of a heightened immune response to HIV.

Peptides for use in vaccination and induction of neutralizing antibodies

Peptides corresponding to epitopes of HTLV-2 proteins are provided. These peptides are immunologically reactive with HTLV-2 specific antibodies. Several of the peptides are sufficiently unreactive to antibodies to HTLV-1 to distinguish between antibodies which recognize HTLV-1 and those which recognize HTLV-2. Thus HTLV-1 infections can be distinguished from HTLV-2 infections. The peptides are useful in assays for detection of HTLV-2 infection or exposure. The peptides are also useful as vaccine compositions against HTLV-2. Antibodies generated in response to immunization by the peptides are also provided.

Peptides for detecting antibodies to HTLV-2

It has now been found that relatively short peptides such as the tripeptide glycyl-prolyl-glycine are able to effectively inhibit HIV infection of cells and syncytia formation between HIV infected and and non-infected cells. The peptides are suitable for therapy of patients infected with HIV and in prevention of HIV infection.

Peptides that block human immunodeficiency virus and methods of use

In accordance with the present invention, novel peptides corresponding to epitopes of human immunodeficiency virus-1 gp120 protein and analogues and homologs thereof are provided. These peptides can be utilized alone or in combination, uncoupled or coupled to other molecules or substrates. The peptides are useful in immunization against human immunodeficiency virus infection and in production of polyclonal and monoclonal antibodies.

Peptides for induction of neutralizing antibodies against human

Peptides corresponding to regions of the human immunodeficiency virus protein gp-120 are provided for eliciting T-cell activation.

Peptides for use in induction of T cell activation against HIV-1

Peptides for HTLV-2 infection diagnosis of, therapy for, vaccination

Four peptides corresponding to regions of the glycoprotein encoded by the env gene of HTLV1 are provided. These peptides which are immunologically reactive with HTLV-1 specific antibodies are useful in assays for detection of HTLV-1 infection or exposure and in compositions to elicit the production of antibodies against HTLV-1 in animals and man.

Peptides for the detection of HTLV-1 infection

A synthetic peptide antigen corresponding to a region of the glycoprotein gp41 encoded by the env gene of HIV-2 is provided. The peptide which is immunologically reactive with HIV-2 specific antibodies is useful in assays for detection of HIV-2 infection or exposure and in compositions to elicit the production of antibodies against HIV-2 in animals including man.

Growing community of inventors

Hovas, Sweden

Anders Vahlne